Life Sciences Tools and Services
Company Overview of SomaLogic, Inc.
SomaLogic, Inc. discovers, develops, and commercializes life science research tools and clinical diagnostic products for biological and medical science applications. It offers SOMAMER REAGENT, a proteomic platform that combines the properties of antibodies and aptamers; and SOMAscan assay, a protein biomarker discovery and development tool for protein measurement solutions. The company also provides diagnostic tests for various diseases and conditions. In addition, it offers protein-measurement assays, kits, and reagents for life science and biopharma researchers. Further, the company also provides protein biomarker-based diagnostics; and chemical reagents as potential therapeutic molecules....
2945 Wilderness Place
Boulder, CO 80301
Founded in 1999
Key Executives for SomaLogic, Inc.
Chief Executive Officer and Director
Founder and Chairman of the Board
Compensation as of Fiscal Year 2016.
SomaLogic, Inc. Key Developments
SomaLogic, Inc. Presents at Deutsche Bank 41st Annual Health Care Conference 2016, May-04-2016 through May-05-2016
Mar 3 16
SomaLogic, Inc. Presents at Deutsche Bank 41st Annual Health Care Conference 2016, May-04-2016 through May-05-2016. Venue: The InterContinental Hotel, 510 Atlantic Ave, Boston, Massachusetts, United States. Presentation Date & Speakers: May-04-2016, Byron D. Hewett, Chief Executive Officer and Director.
SomaLogic, Inc. Signs an Agreement with Bristol-Myers Squibb Company to Provide Expanded Access to its Proprietary SOMAmer Reagents
Jan 11 16
SomaLogic, Inc. announced that it has signed an agreement with the Bristol-Myers Squibb Company to provide expanded access to its proprietary SOMAmer reagents. The agreement covers both the 1,310 reagents available in the current public version of the SOMAscan assay as well as custom SOMAmer reagents developed through SomaLogic's SOMAmer Discovery Service specifically for Bristol-Myers Squibb. Specific terms of the agreement were not disclosed. SOMAmerA (Slow Off-rate Modified Aptamer) reagents are a new generation of protein-binding molecules that combine the best properties of antibodies and traditional aptamers. Each SOMAmerA reagent consists of a unique short single-stranded DNA sequence that incorporates several bases that have been modified to include "protein-like" side chains. These unique chemical properties confer on SOMAmer reagents both high affinity and specificity for their target proteins as well as high durability and reproducibility, making them attractive reagents for virtually every laboratory assay that currently relies on antibodies.
SomaLogic, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 09:40 AM
Oct 31 15
SomaLogic, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 09:40 AM. Venue: Westin Grand Central, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 1, 2016